459 related articles for article (PubMed ID: 23856293)
1. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
[TBL] [Abstract][Full Text] [Related]
2. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.
Kallio A; Zheng A; Dahllund J; Heiskanen KM; Härkönen P
Apoptosis; 2005 Dec; 10(6):1395-410. PubMed ID: 16215679
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
4. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
5. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
[TBL] [Abstract][Full Text] [Related]
6. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
7. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
8. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
[TBL] [Abstract][Full Text] [Related]
9. SIRT3 Silencing Sensitizes Breast Cancer Cells to Cytotoxic Treatments Through an Increment in ROS Production.
Torrens-Mas M; Pons DG; Sastre-Serra J; Oliver J; Roca P
J Cell Biochem; 2017 Feb; 118(2):397-406. PubMed ID: 27420645
[TBL] [Abstract][Full Text] [Related]
10. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
11. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
12. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
13. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
14. COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
Du Y; Shi A; Han B; Li S; Wu D; Jia H; Zheng C; Ren L; Fan Z
Int J Oncol; 2014 Apr; 44(4):1385-93. PubMed ID: 24535190
[TBL] [Abstract][Full Text] [Related]
15. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell.
Lee S; Lee H; Jeong D; Ham J; Park S; Choi EH; Kim SJ
Free Radic Biol Med; 2017 Sep; 110():280-290. PubMed ID: 28666851
[TBL] [Abstract][Full Text] [Related]
16. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
17. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Moriai R; Tsuji N; Moriai M; Kobayashi D; Watanabe N
Breast Cancer Res Treat; 2009 Sep; 117(2):261-71. PubMed ID: 18815881
[TBL] [Abstract][Full Text] [Related]
18. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
Fan P; Wang J; Santen RJ; Yue W
Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
